Catalyst
Slingshot members are tracking this event:
FDA Action Date of September 3rd for Mylan (MYL) and Biocon's Biologics License Application (BLA) For MYL-14010, a Biosimilar to Roche's (RHHBY) Breast Cancer Med Herceptin
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| MYL |
|
|
RHHBY |
|
|
Biocon Ltd. |
|
|
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 13, 2017
Occurred Source:
http://newsroom.mylan.com/2017-07-13-FDA-Oncologic-Drugs-Advisory-Committee-Unanimously-Recommends-Approval-of-Mylan-and-Biocons-Proposed-Biosimilar-Trastuzumab
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Biologics License Application, Bla, Myl-14010, Breast Cancer, Herceptin, Action Date, Fda
